eMedicine Specialties > Ophthalmology > Cornea

Peripheral Ulcerative Keratitis

Author: Ellen N Yu, MD, Consulting Staff, Department of Ophthalmology, St Luke's Medical Center, Quezon City, Philippines
Coauthor(s): C Stephen Foster, MD, FACS, FACR, FAAO, Clinical Professor of Ophthalmology, Harvard Medical School; Consulting Staff, Department of Ophthalmology, Massachusetts Eye and Ear Infirmary; Founder and President, Ocular Immunology and Uveitis Foundation, Massachusetts Eye Research and Surgery Institution
Contributor Information and Disclosures

Updated: Dec 8, 2008

Introduction

Background

Peripheral corneal ulceration is a potentially devastating disorder consisting of a crescent-shaped destructive inflammation at the margin of corneal stroma that is associated with an epithelial defect, presence of stromal inflammatory cells, and progressive stromal degradation and thinning. Commonly referred to as peripheral ulcerative keratitis (PUK), it can quickly produce progressive necrosis of the corneal stroma, leading to perforation and blindness.1

See related CME at Cornea and External Disease.

Pathophysiology

The peripheral cornea has distinct morphologic and immunologic characteristics that predispose it to inflammatory reactions. Unlike the avascular central cornea, the peripheral cornea is closer to limbal conjunctiva and derives part of its nutrient supply from the limbal capillary arcade, a source of immunocompetent cells, for example, macrophages, Langerhans cells, lymphocytes, and plasma cells.2,3 Any inflammatory stimulus in the peripheral cornea that is caused by invasion of microbial organisms (bacteria, virus, fungi, and parasites), immune complex deposition (in systemic immune diseases), trauma, malignancy, or dermatologic conditions may produce local and systemic immune responses, resulting in neutrophil recruitment and complement activation (both classic and alternative pathways) in both tissue and vessels.2

Activated complement components can increase vascular permeability and further generate chemotactic factors for neutrophils (eg, C3a, C5a). Neutrophils, in turn, infiltrate the peripheral cornea and release proteolytic and collagenolytic enzymes, reactive oxygen metabolites, and proinflammatory substances (eg, platelet-activating factor, leukotrienes, prostaglandins), causing dissolution and degradation of the corneal stroma.4,5 In addition, the inflamed limbal conjunctiva itself is capable of producing collagenase, which contributes to stromal degradation.6

Systemic diseases that may cause immune complex deposition at the peripheral cornea and PUK include such collagen vascular diseases as rheumatoid arthritis (RA), Wegener granulomatosis (WG), polyarteritis nodosa (PAN), relapsing polychondritis (RP), and systemic lupus erythematosus (SLE). Infectious conditions, whether systemic (eg, hepatitis, syphilis) or local (eg, herpes simplex keratitis, fungal keratitis), and noninfectious local disorders (eg, Mooren ulcer, marginal keratitis) also may cause PUK.

In summary, the major pathophysiologic mechanism of PUK is a result of degradation and tissue necrosis of corneal stroma produced by degradative enzymes, which are released primarily by neutrophils attracted into the area by diverse stimuli.

Frequency

United States

PUK is uncommon. RA has been reported as the most common collagen vascular disorder that causes PUK, accounting for 34% of noninfectious PUK.6,7,8 PUK may be the initial manifestation of WG and PAN. PUK is rare in patients with RP; only 2 of 112 patients with RP were reported to develop PUK in a clinical review study.9 PUK has also been reported to be associated with SLE, although this is uncommon.3,10 Mooren ulcer is a rare local autoimmune disease associated with PUK, with only 287 cases reported in the world literature, although some of these cases may have been the presenting manifestation of an occult systemic disease rather than true Mooren ulcer.11

Mortality/Morbidity

PUK produces great morbidity from the pain and resultant visual disability. It can be a harbinger of death if the underlying disease is not diagnosed and successfully treated.

Race

No good data are available on racial predilection for PUK.

Sex

Since PUK is more common in people with collagen vascular disorders (especially RA), it is more common in females than in males. However, PUK caused by Mooren ulcer is more common in males than in females.11,12

Age

Age varies and is dependent on the associated systemic or local disorder.

Clinical

History

PUK is frequently a manifestation of an occult systemic disease. Thus, a thorough systemic history is very important and should include chief complaint, characteristics of present illness, past medical history, family history, and a meticulous review of systems.4

  • Ocular symptoms vary, but nonspecific foreign body sensation with or without eye pain, tearing, photophobia, and reduced visual acuity are the most common symptoms for patients with PUK.
  • Loss of vision can occur quickly when PUK progresses.
  • PUK associated with RA, WG, PAN, and RP is often linked with scleritis, and eye pain may be pronounced in these individuals.4 PUK in patients with Mooren ulcer may also produce pain, although there is no scleral involvement.
  • Past medical history and review of systems helps to determine the possible underlying systemic diseases. RA, SLE, PAN, WG, or RP may present with the following symptoms, which should be emphasized in the review of systems12 :
    • General - Constitutional symptoms, such as chills, fever, poor appetite, recent weight loss, and fatigue
    • Skin - Rashes, nodules, vesicles, ulcer, nail changes, and periungual infarcts
    • Respiratory - Coughing, wheezing, pneumonia, and shortness of breath
    • Cardiac - Chest pain or discomfort and dyspnea
    • Gastrointestinal - Abdominal pain, nausea, vomiting, difficulty swallowing, and diarrhea
    • Musculoskeletal - Muscle or joint pain, arthritis, back pain, and limitation of motion
    • Neurologic - Headaches, seizures, psychiatric, paralysis, and numbness/tingling
    • Other systemic symptoms - Deafness, swollen ear lobes, ear infections, vertigo, and noises in ears (suggestive of RP)

Physical

  • Examination should be complete and include an overview of the head (including the nose, mouth, and external ear), trunk, joints, and extremities.4 Skin lesions should also be noted.
  • A complete ophthalmic examination should be performed with special emphasis on the conjunctiva, sclera, and cornea. Anterior chamber, vitreous, and fundus examinations are also important.
  • Patients with PUK typically present with decreased visual acuity (secondary to induced irregular astigmatism), tearing, and eye irritation with or without pain of variable duration.5
  • Slit lamp examination reveals a crescent-shaped destructive lesion of the juxtalimbal corneal stroma associated with an epithelial defect, stromal yellow-white infiltrates composed of inflammatory cells, and varying degrees of corneal stromal thinning (minimal to full thickness) adjacent to the limbus.6
  • In severe cases, the peripheral cornea is progressively destroyed circumferentially and centrally.
  • PUK accompanied by necrotizing scleritis almost always indicates the presence of a potentially lethal systemic disease.4
  • The anterior chamber should be evaluated for depth and inflammation.
  • A posterior segment examination is typically indicated to help determine the underlying etiology.

Causes

The etiologies for developing PUK are multiple and extensive. Connective tissue and vasculitic diseases are the major risk factors. Other disorders that can cause PUK include systemic and local infectious conditions, as well as local degenerative disorders.

The differential diagnosis of PUK is outlined below (Feldman, 2000).4

  • Noninfectious conditions
    • Systemic - RA, SLE, RP, sarcoidosis, progressive systemic sclerosis, rosacea, WG, PAN, giant cell arteritis, inflammatory bowel disease, metabolic conditions, and nutritional deficiencies
    • Local - Mooren ulcer, marginal keratitis, blepharitis (eg, staphylococcal infection, rosacea), contact lens use, chemical injury to the eyes, trauma, surgery, neurotrophic and neuroparalytic causes,  keratoconjunctivitis sicca, Terrien marginal degeneration, pellucid marginal degeneration, and furrow degeneration5
  • Infectious conditions
    • Systemic -Shigella species, tuberculosis, syphilis, hepatitis, HIV, gonococcus, Salmonella species, and bacillary dysentery
    • Local - Herpes simplex keratitis, varicella-zoster keratitis, bacterial keratitis, fungal keratitis, and Acanthamoeba species
  • Masquerade - Malignancy - Leukemia13

More on Peripheral Ulcerative Keratitis

Overview: Peripheral Ulcerative Keratitis
Differential Diagnoses & Workup: Peripheral Ulcerative Keratitis
Treatment & Medication: Peripheral Ulcerative Keratitis
Follow-up: Peripheral Ulcerative Keratitis
Multimedia: Peripheral Ulcerative Keratitis
References

References

  1. Mondino BJ. Inflammatory diseases of the peripheral cornea. Ophthalmology. Apr 1988;95(4):463-72. [Medline].

  2. Shiuey Y, Foster CS. Peripheral ulcerative keratitis and collagen vascular disease. Int Ophthalmol Clin. Winter 1998;38(1):21-32. [Medline].

  3. Messmer EM, Foster CS. Vasculitic peripheral ulcerative keratitis. Surv Ophthalmol. Mar-Apr 1999;43(5):379-96. [Medline].

  4. Foster CS, Sainz de la Maza M. Immunological considerations of the sclera. In: Foster CS, ed. The Sclera. ed. New York: Springer-Verlag; 1993:33-58.

  5. Gregory JK, Foster CS. Peripheral ulcerative keratitis in the collagen vascular diseases. Int Ophthalmol Clin. Winter 1996;36(1):21-30. [Medline].

  6. Eiferman RA, Carothers DJ, Yankeelov JA Jr. Peripheral rheumatoid ulceration and evidence for conjunctival collagenase production. Am J Ophthalmol. May 1979;87(5):703-9. [Medline].

  7. Brown SI, Grayson M. Marginal furrows. A characteristic corneal lesion of rheumatoid arthritis. Arch Ophthalmol. May 1968;79(5):563-7. [Medline].

  8. Tauber J, Sainz de la Maza M, Hoang-Xuan T, et al. An analysis of therapeutic decision making regarding immunosuppressive chemotherapy for peripheral ulcerative keratitis. Cornea. Jan 1990;9(1):66-73. [Medline].

  9. Hoang-Xaun T, Foster CS, Rice BA. Scleritis in relapsing polychondritis. Response to therapy. Ophthalmology. Jul 1990;97(7):892-8. [Medline].

  10. Watson PG, Hazelman BC. The Sclera and Systemic Disorders. Philadelphia: WB Saunders Co; 1976:241.

  11. Sangwan VS, Zafirakis P, Foster CS. Mooren's ulcer: current concepts in management. Indian J Ophthalmol. Mar 1997;45(1):7-17. [Medline].

  12. Tabbara KF. Mooren's ulcer. Int Ophthalmol Clin. Winter 1986;26(4):91-8. [Medline].

  13. Chawla B, Agarwal P, Tandon R, et al. Peripheral ulcerative keratitis with bilateral optic nerve involvement as an initial presentation of acute lymphocytic leukemia in an adult. Int Ophthalmol. Nov 16 2007;[Medline].

  14. Carson DA. Rheumatoid factor. In: Kelley WN, Harris ED Jr, Ruddy S, Sledge CB, eds. Textbook of Rheumatology. 3rd ed. Philadelphia: WB Saunders Co; 1989:664-679.

  15. Lüdemann G, Gross WL. Autoantibodies against cytoplasmic structures of neutrophil granulocytes in Wegener's granulomatosis. Clin Exp Immunol. Aug 1987;69(2):350-7. [Medline].

  16. Savage CO, Winearls CG, Jones S, et al. Prospective study of radioimmunoassay for antibodies against neutrophil cytoplasm in diagnosis of systemic vasculitis. Lancet. Jun 20 1987;1(8547):1389-93. [Medline].

  17. Nolle B, Specks U, Ludemann J, et al. Anticytoplasmic autoantibodies: their immunodiagnostic value in Wegener granulomatosis. Ann Intern Med. Jul 1 1989;111(1):28-40. [Medline].

  18. Squirrell DM, Winfield J, Amos RS. Peripheral ulcerative keratitis 'corneal melt' and rheumatoid arthritis: a case series. Rheumatology (Oxford). Dec 1999;38(12):1245-8. [Medline].

  19. Liegner JT, Yee RW, Wild JH. Topical cyclosporine therapy for ulcerative keratitis associated with rheumatoid arthritis. Am J Ophthalmol. May 15 1990;109(5):610-2. [Medline].

  20. Miyazaki D, Tominaga T, Kakimaru-Hasegawa A, et al. Therapeutic effects of tacrolimus ointment for refractory ocular surface inflammatory diseases. Ophthalmology. Jun 2008;115(6):988-992.e5. [Medline].

  21. Chen J, Xie H, Wang Z, et al. Mooren's ulcer in China: a study of clinical characteristics and treatment. Br J Ophthalmol. Nov 2000;84(11):1244-9. [Medline].

  22. Clewes AR, Dawson JK, Kaye S, et al. Peripheral ulcerative keratitis in rheumatoid arthritis: successful use of intravenous cyclophosphamide and comparison of clinical and serological characteristics. Ann Rheum Dis. Jun 2005;64(6):961-2. [Medline].

  23. Thomas JW, Pflugfelder SC. Therapy of progressive rheumatoid arthritis-associated corneal ulceration with infliximab. Cornea. Aug 2005;24(6):742-4. [Medline].

  24. Atchia II, Kidd CE, Bell RW. Rheumatoid arthritis-associated necrotizing scleritis and peripheral ulcerative keratitis treated successfully with infliximab. J Clin Rheumatol. Dec 2006;12(6):291-3. [Medline].

  25. Lambiase A, Sacchetti M, Sgrulletta R, et al. Amniotic membrane transplantation associated with conjunctival peritomy in the management of Mooren's ulcer: a case report. Eur J Ophthalmol. Mar-Apr 2005;15(2):274-6. [Medline].

  26. Prabhasawat P, Tesavibul N, Komolsuradej W. Single and multilayer amniotic membrane transplantation for persistent corneal epithelial defect with and without stromal thinning and perforation. Br J Ophthalmol. Dec 2001;85(12):1455-63. [Medline].

  27. Tseng SC. Amniotic membrane transplantation for persistent corneal epithelial defect. Br J Ophthalmol. Dec 2001;85(12):1400-1. [Medline].

  28. Bullen CL, Liesegang TJ, McDonald TJ, et al. Ocular complications of Wegener's granulomatosis. Ophthalmology. Mar 1983;90(3):279-90. [Medline].

  29. Foster CS, Forstot SL, Wilson LA. Mortality rate in rheumatoid arthritis patients developing necrotizing scleritis or peripheral ulcerative keratitis. Effects of systemic immunosuppression. Ophthalmology. Oct 1984;91(10):1253-63. [Medline].

  30. Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. Oct 2000;130(4):492-513. [Medline].

  31. Robin JB, Schanzlin DJ, Verity SM, et al. Peripheral corneal disorders. Surv Ophthalmol. Jul-Aug 1986;31(1):1-36. [Medline].

  32. Watson PG, Hayreh SS. Scleritis and episcleritis. Br J Ophthalmol. Mar 1976;60(3):163-91. [Medline].

Further Reading

Keywords

peripheral ulcerative keratitis, peripheral corneal ulceration, PUK, marginal corneal ulcer, corneal stroma, corneal perforation, rheumatoid arthritis, RA, vision loss, blindness

Contributor Information and Disclosures

Author

Ellen N Yu, MD, Consulting Staff, Department of Ophthalmology, St Luke's Medical Center, Quezon City, Philippines
Ellen N Yu, MD is a member of the following medical societies: American Academy of Ophthalmology and Philippine Medical Association
Disclosure: Nothing to disclose.

Coauthor(s)

C Stephen Foster, MD, FACS, FACR, FAAO, Clinical Professor of Ophthalmology, Harvard Medical School; Consulting Staff, Department of Ophthalmology, Massachusetts Eye and Ear Infirmary; Founder and President, Ocular Immunology and Uveitis Foundation, Massachusetts Eye Research and Surgery Institution
C Stephen Foster, MD, FACS, FACR, FAAO is a member of the following medical societies: Alpha Omega Alpha, American Academy of Ophthalmology, American Association of Immunologists, American College of Rheumatology, American College of Surgeons, American Federation for Clinical Research, American Medical Association, American Society for Microbiology, American Uveitis Society, Association for Research in Vision and Ophthalmology, Massachusetts Medical Society, Royal Society of Medicine, and Sigma Xi
Disclosure: Nothing to disclose.

Medical Editor

Fernando H Murillo-Lopez, MD, Senior Surgeon, Unidad Privada de Oftalmologia CEMES
Fernando H Murillo-Lopez, MD is a member of the following medical societies: American Academy of Ophthalmology
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: Nothing to disclose.

Managing Editor

Christopher J Rapuano, MD, Professor, Department of Ophthalmology, Jefferson Medical College of Thomas Jefferson University; Co-Chairman of the Cornea Service, Co-Chairman of Refractive Surgery Department, Wills Eye Institute
Christopher J Rapuano, MD is a member of the following medical societies: American Academy of Ophthalmology, American Society of Cataract and Refractive Surgery, Eye Bank Association of America, Pennsylvania Medical Society, and Philadelphia County Medical Society
Disclosure: Allergan Honoraria Speaking and teaching; Allergan Consulting fee Consulting; Alcon Honoraria Speaking and teaching; Inspire Honoraria Speaking and teaching; RPS Ownership interest Other

CME Editor

Lance L Brown, OD, MD, Ophthalmologist, Affiliated With Freeman Hospital and St John's Hospital, Regional Eye Center, Joplin, Missouri
Disclosure: Nothing to disclose.

Chief Editor

Hampton Roy Sr, MD, Associate Clinical Professor, Department of Ophthalmology, University of Arkansas for Medical Sciences
Hampton Roy Sr, MD is a member of the following medical societies: American Academy of Ophthalmology, American College of Surgeons, and Pan-American Association of Ophthalmology
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.